Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, 10x Genomics Inc’s stock clocked out at $13.46, up 0.75% from its previous closing price of $13.36. In other words, the price has increased by $0.75 from its previous closing price. On the day, 2.24 million shares were traded. TXG stock price reached its highest trading level at $13.71 during the session, while it also had its lowest trading level at $13.24.
Ratios:
To gain a deeper understanding of TXG’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.46. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.84. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 13, 2025, Downgraded its rating to Market Perform and sets its target price to $12 from $25 previously.
On September 03, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $35.
Jefferies Upgraded its Hold to Buy on July 22, 2024, while the target price for the stock was maintained at $24.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 22 ’25 when Saxonov Serge sold 9,343 shares for $8.30 per share. The transaction valued at 77,540 led to the insider holds 1,083,625 shares of the business.
Hindson Benjamin J. sold 7,485 shares of TXG for $62,120 on May 22 ’25. The insider now owns 448,374 shares after completing the transaction at $8.30 per share. On May 22 ’25, another insider, Taich Adam, who serves as the Chief Financial Officer of the company, sold 4,044 shares for $8.30 each. As a result, the insider received 33,562 and left with 331,588 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 1675635456 and an Enterprise Value of 1315122944. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.60 while its Price-to-Book (P/B) ratio in mrq is 2.17. Its current Enterprise Value per Revenue stands at 2.041 whereas that against EBITDA is -11.864.
Stock Price History:
The Beta on a monthly basis for TXG is 2.00, which has changed by -0.40283942 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $24.76, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is 9.69%, while the 200-Day Moving Average is calculated to be 10.92%.
Shares Statistics:
It appears that TXG traded 3.76M shares on average per day over the past three months and 3765720 shares per day over the past ten days. A total of 114.36M shares are outstanding, with a floating share count of 110.26M. Insiders hold about 11.43% of the company’s shares, while institutions hold 98.39% stake in the company. Shares short for TXG as of 1753920000 were 14455823 with a Short Ratio of 3.85, compared to 1751241600 on 14806000. Therefore, it implies a Short% of Shares Outstanding of 14455823 and a Short% of Float of 18.64.
Earnings Estimates
Investors are keenly observing as 2.0 analysts analyze and rate the current performance of 10x Genomics Inc (TXG) in the stock market.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.01 and low estimates of -$0.07.
Analysts are recommending an EPS of between $0.39 and -$0.22 for the fiscal current year, implying an average EPS of $0.09. EPS for the following year is -$0.17, with 2.0 analysts recommending between -$0.04 and -$0.29.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $142.64M. It ranges from a high estimate of $145.6M to a low estimate of $139.56M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $151.65MFor the next quarter, 14 analysts are estimating revenue of $150.84M. There is a high estimate of $157.8M for the next quarter, whereas the lowest estimate is $146M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $625.3M, while the lowest revenue estimate was $573.71M, resulting in an average revenue estimate of $615.81M. In the same quarter a year ago, actual revenue was $610.78MBased on 15 analysts’ estimates, the company’s revenue will be $609.08M in the next fiscal year. The high estimate is $626.4M and the low estimate is $592.9M.
